A Randomised, Open-Label, Phase III Study Of RPR1089881 IV Every Three Weeks Versus Capecitabine (Xeolda) Tablets Twice Daily For Two Weeks In Three Week Cycles In Patients With Metastatic Breast Cancer Progressing After Taxanes. (Aventis)

  • Rea, Daniel (Principal Investigator)

Project Details

Short titleA Randomised, Open-Label, Phase III Study Of RPR1089881 IV Every Three Weeks Versus Capecitabine (Xeolda) Tablets Twice Daily For Two Weeks In Three Week Cycles In Patients With Metastatic Breast Cancer Progressing After Taxanes. (Aventis)
StatusFinished
Effective start/end date1/01/05 → 31/12/07

Funding

  • Queen Elizabeth Hospital Birmingham